FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Exjade (deferasirox) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Myelodysplastic Syndromes
• Sickle Cell Disease
• Transfusion-dependent Anemia

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)